文献速递心力衰竭与心肌病

2型糖尿病对替尔泊肽在射血分数保留心衰合并肥胖患者中疗效的影响:预设分层分析

Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

SUMMIT试验预设分层分析纳入731例HFpEF且BMI≥30 kg/m²患者,随机接受替尔泊肽或安慰剂中位104周。替尔泊肽降低心血管死亡或心衰恶化事件风险(HR 0.62),该获益在有无2型糖尿病患者中相似(Pinteraction=0.95),尽管糖尿病患者体重下降幅度较小(10.4% vs 12.9%,Pinteraction=0.04),但心衰相关临床获益及心脏结构改善无差异。

要点

  • 替尔泊肽在HFpEF合并肥胖患者中降低心血管死亡或心衰恶化风险,有无糖尿病获益一致。
  • 糖尿病患者体重下降幅度较小,但心衰症状、功能及心脏结构改善与无糖尿病者相似。
  • 心衰获益可能不能仅通过体重变化幅度来评估。

核心结论

  • 尽管2型糖尿病患者体重下降幅度较小,替尔泊肽在HFpEF合并肥胖患者中仍带来相似的心衰结局和临床状态改善。

研究设计与样本

  • SUMMIT为双盲随机对照试验,731例HFpEF且BMI≥30 kg/m²患者按1:1随机接受替尔泊肽(最高15 mg每周皮下注射)或安慰剂,中位104周,糖尿病史为随机分层因素。

主要发现

  • 替尔泊肽组心血管死亡或心衰恶化事件发生率更低(HR 0.62;95%CI 0.41-0.95;P=0.026),主要与心衰恶化事件减少相关。
  • 有无糖尿病患者的疗效相似:糖尿病者HR 0.64(95%CI 0.35-1.15),无糖尿病者HR 0.61(95%CI 0.33-1.10),Pinteraction=0.95。
  • 52周时糖尿病患者体重下降10.4%(95%CI 8.7%-12.2%),无糖尿病者下降12.9%(95%CI 11.2%-14.6%),Pinteraction=0.04。
  • 有无糖尿病患者的心室质量和心旁脂肪下降程度相似。

临床怎么用

  • 对于HFpEF合并肥胖的2型糖尿病患者,替尔泊肽可带来与无糖尿病者相似的心衰获益,不应因体重下降幅度较小而低估其临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Incretin-based therapies are used to treat type 2 diabetes and obesity, but the presence of diabetes diminishes the magnitude of weight loss produced by these drugs in people with obesity. It is not known whether this attenuated weight change is relevant to the clinical benefits of these drugs in heart failure. OBJECTIVES: The goal of this study was to assess the influence of diabetes on the efficacy and safety of tirzepatide in the SUMMIT trial. METHODS: In a double-blind trial, 731 patients with heart failure and a preserved ejection fraction (HFpEF) with a body mass index ≥30 kg/m2 were randomly assigned in a 1:1 ratio to receive tirzepatide (up to 15 mg subcutaneously weekly) or placebo for a median of 104 weeks. History of diabetes was a stratification variable for randomization. The 2 primary outcomes were: 1) time to first cardiovascular death or worsening heart failure event; and 2) change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 52 weeks. Paired cardiac magnetic resonance imaging was used to assess changes in left ventricular mass and paracardiac fat at 52 weeks. RESULTS: Overall, cardiovascular death or worsening heart failure events occurred less frequently in the tirzepatide group (HR: 0.62; 95% CI: 0.41-0.95; P = 0.026), primarily related to fewer worsening heart failure events. The effect in patients with or without diabetes was similar: HR of 0.64 (95% CI: 0.35-1.15) in patients with diabetes and 0.61 (95% CI: 0.33-1.10) in patients without diabetes (Pinteraction = 0.95). The magnitude of the improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, 6-minute walk distance, quality-of-life scores, and NYHA functional class with tirzepatide was statistically significant and did not differ in patients with and without type 2 diabetes. At 52 weeks, weight loss was less pronounced in patients with type 2 diabetes; patients with diabetes lost 10.4% (95% CI: 8.7%-12.2%) of body weight, compared with 12.9% (95% CI: 11.2%-14.6%) in patients without diabetes (Pinteraction = 0.04). However, patients with or without diabetes showed similar decreases in visceral adiposity (as reflected by the decline in paracardiac fat) and in left ventricular mass. CONCLUSIONS: Despite less pronounced weight loss, patients with HFpEF, obesity, and type 2 diabetes responded favorably to tirzepatide. This favorable response was reflected by a reduced risk of adverse heart failure outcomes and improved health status, quality of life, and functional capacity, as well as a decrease in left ventricular mass and paracardiac fat, to a degree that was similar to that in patients without diabetes. These observations raise the possibility that the heart failure benefits of incretin-based drugs may not be faithfully estimated by measuring the magnitude of the change in body weight. (SUMMIT [A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity]; NCT04847557).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Packer, Zile, Kramer, et al. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. J Am Coll Cardiol. 2025. PMID: 40903131. doi:10.1016/j.jacc.2025.06.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。